Table 2. Matched population baseline characteristics.
| Non-adherent Group | Nephrocare Group | Total matched | p | |
|---|---|---|---|---|
| Number | 3480 | 3480 | 6960 | |
| Age (years) (median, pc 25–75) | 71.0 (60.0–78.0) | 70.0 (60.0–77.0) | 70.0 (60.0–78.0) | 0.020a |
| Age groups: ≤ 40 years, n (%) | 229 (6.6%) | 229 (6.6%) | 458 (6.6%) | |
| 41–64 years n (%) | 929 (26.7%) | 951 (27.3%) | 1880 (27.0%) | 0.834 b |
| >65 years n (%) | 2322 (66.7%) | 2300 (66.1%) | 4622 (66.4%%) | |
| Sex Male, n (%) | 2044 (58.7%) | 2000 (57.5%) | 4044 (58.1%) | 0.296 b |
| Health provider | 0.552 b | |||
| Public n (%) | 1313 (37.7%) | 1288 (37.0%) | 2601 (37.4%) | |
| Private-Non-for-profit n (%) | 2167 (62.3%) | 2192 (63.0%) | 4359 (62.6%) | |
| SBP initial (mmHg) (median, pc 25–75) | 130 (120–140) | 130 (120–140) | 130 (120–140) | 0.684 b |
| DBP initial (mmHg) (median, pc 25–75) | 80.0 (70.0–80.0) | 78.5 (70.0–80.0) | 80.0 (70.0–80.0) | 0.122 b |
| Nefropathies | 0.001 b | |||
| Vascular, n (%) | 1730 (49.9%) | 1573 (45.4%) | 3303 (47.7%) | |
| Diabetics, n (%) | 514 (14.8%) | 493 (14.2%) | 1007 (14.5%) | |
| Obstructive Tubulo-intersticial, n (%) | 216 (6.2%) | 172 (5.0%) | 388 (5.6%) | |
| Glomerulopathies, n (%) | 101 (2.9%) | 164 (4.7%) | 265 (3.8%) | |
| Cardiovascular risk factors and Comorbidities | ||||
| Arterial Hypertension, n (%) | 3023 (86.9%) | 3003 (86.3%) | 6026 (86.6%) | 0.504 b |
| Diabetes, n (%) | 1399 (40.2%) | 1396 (40.1%) | 2795 (40.2%) | 0.961 b |
| Smoking, n (%) | 250 (7.2%) | 242 (7.0%) | 492 (7.1%) | 0.743 b |
| Obesity, n (%) | 1095 (38.9%) | 1080 (38.9%) | 2175 (38.9%) | 1.000 b |
| CV comorbidities, # n (%) | 1113 (32.0%) | 1100 (31.6%) | 2213 (31.8%) | 0.757 b |
| eGFR initial (ml/min/1.73 m2) (median, pc 25–75) | 44.32 (33.51–57.44) | 42.78 (33.02–56.86) | 43.49 (33.33–57.23) | 0.024a |
| CKD stages at inclusion | ||||
| I, n (%) | 273 (7.8%) | 317 (9.1%) | 590 (8.5%) | 0.230 b |
| II, n (%) | 490 (14.1%) | 459 (13.2%) | 949 (13.6%) | |
| III, n (%) | 2121 (60.9%) | 2105 (60.5%) | 4226 (60.7%) | |
| IV, n (%) | 521 (15.0%) | 536 (15.4%) | 1057 (15.2%) | |
| V, n (%) | 75 (2.2%) | 63 (1.8%) | 138 (2.0%) | |
| Proteinuria | ||||
| No proteinuria | 2434 (69.9%) | 2422 (69.6%) | 4856 (69.8%) | 0.892 b |
| <500 mg/day, n (%) | 553 (15.9%) | 551 (15.8%) | 1104 (15.9%) | |
| ≥500 mg/day, n (%) | 493 (14.2%) | 507 (14.6%) | 1000 (14.4%) | |
| Initial treatment | ||||
| RASB n (%) | 2026 (58.3%) | 2056 (59.1%) | 4082 (58.6%) | 0.480 b |
CV = Cardiovascular comorbidities # = ischemic heart disease, chronic heart failure, peripheral arteriopathy and/or stroke.
SBP = Systolic blood pressure, DBP = Diastolic blood pressure, PCR = urine protein-creatinine ratio, RASB = Renin-angiotensin system blockade.
Statistics: aTest Mann Whitney,
t b est Chi2.